Publication | Open Access
LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
70
Citations
1
References
2023
Year
Keynote-671 StudyPerioperative PembrolizumabMedicinePathologyBronchial NeoplasmLba56 Overall SurvivalCancer TreatmentOncologyRadiation OncologyLung Cancer
| Year | Citations | |
|---|---|---|
Page 1
Page 1